Close Menu
    Facebook X (Twitter) Instagram
    BusinessNews.phBusinessNews.ph
    Subscribe
    • Top Stories
    • Business
    • Events / Conventions
    • National
    • Technology
    BusinessNews.phBusinessNews.ph
    Home » Suntrap Life Technologies Discovers Natural anti-COVID-19 Compound
    Medical

    Suntrap Life Technologies Discovers Natural anti-COVID-19 Compound

    By Marie JonesDecember 23, 2020
    Share
    Facebook Twitter LinkedIn Pinterest Email

    ‘LeSoleil’, a naturally active compound, was discovered as a therapeutic candidate for use against COVID-19. As the new coronavirus began to spread globally, Suntrap Life Technologies Ltd established a special research team. The project, “Research on Anti-New Coronavirus (COVID-19) Prevention Products”, was launched in an emergency situation. Working from the naturally active compounds screening and discovery platform developed by the International Drug Discovery Network Unites (IDDNU)*, the Suntrap research team conducted high throughput virtual screening of all naturally active compounds in the library, aiming to isolate compounds with a potent antiviral activity while ensuring safety.

    Consequently, ‘LeSoleil’, a potential therapeutic treatment was discovered. After further evaluation of its antiviral activity and safety, a sensitivity experiment with COVID-19 and ‘LeSoleil’ was scheduled in conjunction with Guangdong Provincial Center for Disease Control and Prevention and Guangdong Provincial Institute of Public Health. With core R&D progressing smoothly, the effective prevention, and treatment, of COVID-19 were coming into view.

    The sensitivity experiment was started in August, lasting one month. The results indicated ‘LeSoleil’ has a potent in vitro inhibitory effect on COVID-19, with great potential to become a drug candidate. The experimental details showed that the TC50 (Half Toxicity Concentration) of ‘LeSoleil’ is 71.16 nM, within which the highest inhibitory rate for COVID-19 reached 99.41%. In addition, ‘LeSoleil’ retained a high inhibitory effect against COVID-19 even at low concentration, which has been particularly prominent in several verification experiments. The images show the viability of cells at a concentration of 114.8 nM, with an unexpected inhibition rate up to 63.06%.

    Furthermore, the in vivo experiment showed LD50 of ‘LeSoleil’ is above 2000 mg/kg. As a naturally occurring compound, the plant-derived ‘LeSoleil’ has the advantages of low toxicity, good tolerance, and high accessibility, which provide a guarantee for the rapid development of multi-dose protective and therapeutic drug products.

    The research team completed the formulation of “ShengPu No.1” and “ShengPu No.2”, which provide protection against COVID-19 in the nasal cavity and the oral cavity, respectively, in a spray dosage form. In these formulations, the antiviral effects of ‘LeSoleil’ remain the best while ensuring safety. At the same time, drugs and clinically therapeutic formulations for the treatment of COVID-19 are being further explored.

    Suntrap researchers hope to develop effective drugs for the prevention and treatment of the broad-spectrum coronavirus as soon as possible.

    *http://suntrap-centre.com/iddnu, http://www.suntrap.com

    Contact:
    Suntrap Life Technologies Ltd.
    Zoe Zhou, Media Supervisor
    E: 2113@suntrap.com
    T: +86 18825197167

    The copyright in this article belongs to Suntrap Life Technologies Ltd.
    22 Longrong Road, Hualong Town, Panyu District, Guangzhou, China.
    Any reproduction must cite Suntrap Life Technologies Ltd, http://www.suntrap.com as the source.

    For the latest business and finance news in Asia - Business News Asia
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

    June 9, 2025

    Traditional Chinese Medicine Consumption Shows Promising Outlook, with Neautus’s Market Leadership Becoming Increasingly Evident

    June 3, 2025

    First patient dosed in YK012 trial-the world’s first TCE therapy for primary membranous nephropathy

    May 29, 2025
    Latest News

    10 winners selected at 8th edition of Start-up Express

    June 12, 2025

    This Technology is Conquering the World: Neutrinovoltaics Redefining Global Infrastructure

    June 11, 2025

    HKTDC Design Gallery x STICKYLINE present: “Love HK” Exhibition

    June 11, 2025

    Blockpass partners with CryptoSwift to deliver global Travel Rule Compliance

    June 11, 2025

    U.S. Polo Assn. Returns as Official Apparel and Jersey Partner for Chestertons Polo in the Park in Downtown London

    June 10, 2025

    UK MOD Signs Protector Support Contract with GA-ASI

    June 10, 2025

    New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises

    June 9, 2025

    SRKay Consulting Group Releases Research Report: ‘From Legal Frameworks to Successful Operations’–A Strategic Playbook for India Market Entry

    June 9, 2025

    Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

    June 9, 2025

    Latest Firewall Vulnerability Reinforces Need for Post-Breach Privileged Access Controls – TACACS.net Offers a Critical Layer

    June 6, 2025

    TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis

    June 6, 2025

    Naoris Protocol Expands into the Nordics with Strategic Consulting Hub in Oslo

    June 5, 2025

    TF International Facilitates Hong Kong’s Successful Issuance of First Central Asian Sovereign Bond

    June 5, 2025

    LIMA’25 Wraps up with RM11 Billion in Deals and Record Global Participation

    June 4, 2025

    Global Communities Unite at centralwOrld as Thailand Steps Forward on Global LGBTQ+ Stage with Central Pattana’s Pride For All

    June 4, 2025
    BusinessNews.ph
    • Home
    • Business News Asia
    • Cebu Lifestyle Channel
    • Property News
    • Events News Asia.com
    • Contact Us
    • Cebu Business News
    © 2025 All Rights Reserved | BusinessNews.ph

    Type above and press Enter to search. Press Esc to cancel.